FIGURE 2.

Different generations of CARs and development history. (a) The construction of 1st, 2nd, 3rd, 4th, and 5th generation CARs; (b) historic timeline of the development of CAR‐T cells. ALL, acute lymphocytic leukemia; CAR, chimeric antigen receptor; CTL‐019, tisagenlecleuel; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; HC, hematological cancer; ide‐cel, idecabtagene vicleucel; JAK, Janus kinase; KTE‐X19, brexucabtagene autoleucel; LBCL, large B cell lymphoma; liso‐cel, lisocabtagene maraleucel; MCL, mantle cell lymphoma; NFATD, nuclear factor of activated T cells; NHL, non‐Hodgkin lymphoma; r/r, relapsed/refractory; STAT, signal transducer and activator of transcription